Published on
May 6, 2022

Weekly Headlines | May 6th, 2022

Helping investors discover, understand, and stay up-to-date on investment opportunities within the Psychedelic industry.


Performance of psychedelic public companies this past week.

Company News

COMPASS Pathways ($CMPS) provided positive data from their Phase II clinical trials demonstrating the potential of COMP360 psilocybin therapy in anorexia nervosa and severe treatment-resistant depression. Press Release

Optimi Health ($OPTI | $OPTHF) has been granted an amendment to their controlled substances dealer’s licence by Health Canada, enabling Optimi to expand their capacity to produce natural, GMP psilocybin as well as extracting psilocin for use in clinical trials. Press Release

PharmaTher Holdings ($PHRM | $PHRRF) has been granted a patent for the formulation and production process of ketamine and ketamine analogs. PharmaTher is developing a ketamine injection and infusion product to support their expected clinical studies for Parkinson’s disease and Lou Gehrig’s disease. Press Release

PsyBio Therapeutics ($PSYB | $PSYBF) expanded their pre-clinical pipeline by initiating blood-brain barrier permeability testing. This additional testing procedure is expected to provide a comprehensive, state of the art research methodology with which PsyBio's portfolio of compounds can be more readily and rapidly developed. Press Release

Wellbeing Digital Sciences ($MEDI | $KONEF) appointed Dr. Michael Ho as the new Medical Director of the MindScape Ketamine & Infusion Therapy Clinic. Dr. Michael Ho is an award winning anesthesiologist who serves as the director of Safe Sleep Anesthesia Texas. Press Release

PharmaDrug ($PHRX) selected a final lead drug candidate from a short list of six DMT analogue molecules in collaboration with the Terasaki Institute for Biomedical Innovation. Press Release

Nova Mentis Life Science ($NOVA | $NMLSF) advanced their psilocybin-based drug development program following the receipt of a Health Canada approved psilocybin import permit. The approval allows Nova to ship their proprietary psilocybin drug to formulate and manufacture psilocybin microdose capsules for their' planned clinical study. Press Release

MindBio Therapeutics ($BLR | $BLRZF) completed their 12 month Phase 1 clinical trial microdosing LSD in 80 healthy participants. The randomized, double-blind, placebo controlled Phase I clinical trial is the largest safety study of its kind. Press Release

Wesana Health Holdings ($WESA | $WSNAF) provided operational updates. Highlights included broadening SANA-013’s lead indication to treat major depressive disorder, received positive feedback from pre-IND meeting with FDA on SANA-013 and reported positive findings from animal study on novel depression treatment protocol combining psilocybin and cannabidiol. Press Release


Smithsonian: Why Psychedelic Drugs May Become a Key Treatment for PTSD and Depression

FOX: Research On Psychedelics As PTSD Treatment Shows Positive Results

Business Insider:
Healthcare VCs Are Dipping Their Toes Into Psychedelics

The Telegraph: Could A Psychedelic Retreat Cure My Lifelong Hang Ups?

Be the first to see new company features, exclusive interviews and breaking news in the psychedelic markets. Subscribe now.